Fruzaqla Delays Colorectal Cancer Progression, Prolongs Patient Survival
January 23rd 2024Findings presented at the 2024 Gastrointestinal Cancers Symposium support Fruzaqla’s potential to provide an improved survival benefit and quality of life for those with previously treated metastatic colorectal cancer.
Kisqali Plus Endocrine Therapy Improves Survival in HR+/HER2– Breast Cancer
December 6th 2023Patients with HR-positive HER2-negative advanced breast cancer, including elderly patients, derived a progression-free and overall survival benefit with Kisqali plus endocrine therapy compared with placebo plus endocrine therapy.
Avastin Regimen Improves Survival in Ovarian Cancer, Including Some HRD-Positive Tumors
June 3rd 2023A progression-free survival benefit was observed in patients with advanced ovarian cancer including those with homologous recombination deficient-positive status who were treated with frontline chemo plus Avastin and Imfinzi followed by maintenance therapy with an Avastin regimen.